title: Seminal Helicobacter pylori treatment improves sperm motility in infertile asthenozoospermic men.
abstract: OBJECTIVE
  To assess the effect of treatment of seminal Helicobacter pylori in infertile asthenozoospermic men.
  
  
  METHODS
  In all, 223 infertile asthenozoospermic men were consecutively selected. They were subjected to history taking, clinical examination, semen analysis, and estimation of H pylori IgA antibodies in their seminal fluid. Infertile men with high seminal H pylori IgA were subjected to triple drug treatment, omeprazole, 20 mg; tinidazole, 500 mg; and clarithromycin, 250 mg twice a day for 2 weeks. Semen analysis as well as H pylori IgA antibodies was estimated after 3 months.
  
  
  RESULTS
  In all, 22 of 223 men (9.87%) demonstrated H pylori IgA antibodies in their seminal plasma. After treatment, mean seminal H pylori IgA levels demonstrated significant decrease (1.55 ± 0.4 vs 0.52 ± 0.26; 95% confidence interval, 0.83-1.21; P = .001) concomitant with improved progressive as well as nonprogressive sperm motility. H pylori IgA antibodies demonstrated significant negative correlation with progressive sperm motility, nonprogressive sperm motility, normal sperm morphology, and significant positive correlation with immotile sperm motility.
  
  
  CONCLUSIONS
  H pylori treatment significantly improves sperm motility in infertile asthenozoospermic men with elevated seminal H pylori IgA.
authors.affiliation: Dermatology, Venereology & Andrology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
authors.forename: Yehia
authors.initials: Y
authors.lastname: El-Garem
authors.affiliation: Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
authors.forename: Mohamed
authors.initials: M
authors.lastname: El-Sawy
authors.affiliation: Department of Andrology & Sexology, Faculty of Medicine, Cairo University, Cairo, Egypt. Electronic address: taymour1155@link.net.
authors.forename: Taymour
authors.initials: T
authors.lastname: Mostafa
mesh_terms: D000328:Adult; D000907:Antibodies, Bacterial / Q000032:analysis / Q000276:immunology; D053627:Asthenozoospermia / Q000175:diagnosis*; D017291:Clarithromycin / Q000627:therapeutic use; D015331:Cohort Studies; D016001:Confidence Intervals; D004359:Drug Therapy, Combination; D005500:Follow-Up Studies; D016481:Helicobacter Infections / Q000175:diagnosis* / Q000188:drug therapy; D016480:Helicobacter pylori / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007070:Immunoglobulin A / Q000276:immunology*; D007248:Infertility, Male / Q000175:diagnosis; D008297:Male; D009853:Omeprazole / Q000627:therapeutic use; D011446:Prospective Studies; D012661:Semen / Q000382:microbiology*; D055101:Semen Analysis; D013081:Sperm Motility / Q000187:drug effects*; D014011:Tinidazole / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000907:Antibodies, Bacterial; D007070:Immunoglobulin A; D014011:Tinidazole; D017291:Clarithromycin; D009853:Omeprazole